Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), shows promise for treating idiopathic angioedema, according to data from a small Phase 4 trial. In the study, treatment for roughly six months with Xolair as an add-on therapy lessened disease activity when compared to…
Takhzyro (lanadelumab), an under-the skin injection therapy to prevent attacks in people with hereditary angioedema (HAE), has won the 2022 Prix Galien Canada Innovative Product Award. The prestigious annual award is given to a company — here, Takeda Pharmaceuticals — in recognition of a marketed product that has “made the most…
Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE) in Israel can now receive once-daily Orladeyo (berotralstat) to prevent HAE-related swelling attacks. The decision to approve the medication by the Israeli Ministry of Health follows similar decisions in Canada and Switzerland, as well as…
Donidalorsen, a small molecule therapy being developed by Ionis Pharmaceuticals, continues to be safe and to prevent swelling attacks when taken for up to one year by people with hereditary angioedema (HAE), trial data show. The open-label extension study (NCT04307381) is ongoing in patients who completed a placebo-controlled…
A single dose of the extended-release formulation of PHA121 — an investigational molecule under development for the prevention and treatment of swelling attacks associated with hereditary angioedema (HAE) — led to sustained, therapeutic levels of the medication in the bloodstream of participants. That’s according to promising data from…
Most hereditary angioedema (HAE) patients in a Phase 1/2 clinical trial have gone months without a swelling attack following a single infusion of the experimental gene-editing therapy NTLA-2002. The remaining patients haven’t yet reached the pre-specified 16-week follow-up period for their attack rates to be analyzed, but their comparable…
People with hereditary angioedema (HAE) who switched to Orladeyo (berotralstat) from other preventive treatments generally experience a reduction in swelling attacks. That is according to real-world data presented by BioCryst Pharmaceuticals, Orladeyo’s developer, during the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma…
A Japanese woman was diagnosed with a rare case of non-episodic angioedema associated with eosinophilia (NEAE), with remarkably high levels of immune eosinophil cells in her bloodstream, a recent case report describes. Swelling in her legs and feet, and associated weight gain, were successfully treated with the anti-inflammatory…
An ACE inhibitor, a common medication to control blood pressure, triggered small bowel angioedema in a 34-year-old woman, according to a case report. “Given the high prevalence of ACEi [ACE inhibitor] prescriptions, it is an important mimic to consider for other chronic intermittent intestinal diseases,” because stopping their use…
An orally disintegrating tablet (ODT) formulation of sebetralstat, an investigational on-demand treatment for swelling attacks in hereditary angioedema (HAE) patients, is processed by the body in a similar way to its film-coated tablets, according to data from a Phase 1 clinical trial. Researchers are investigating these ODT tablets…
Get regular updates to your inbox.